^
Association details:
| Biomarker: | NRAS mutation |
|---|---|
| Cancer: | Melanoma |
| Drug: | Cotellic (cobimetinib) (MEK1 inhibitor) + belvarafenib (RG6185) (pan-RAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
529P - Potential impact of molecularly-selected treatment in patients with endocrine neoplasms at a tertiary university hospital
Published date:
09/13/2021
Excerpt:
Among 19 pts with NRASm melanoma, 5 (26.3%) pts had a confirmed partial response (cPR) and 8 (42.1%) pts reached stable disease. For BRAFm melanoma, 3 out of 9 pts (33.3%) with a canonical V600 mutation and 3 out of 6 pts (50.0%) with non-canonical mutations achieved cPR. Two out of 2 pts (100.0%) with non-canonical BRAFm NSCLC achieved PR (one unconfirmed). Three additional PR occurred: 2 KRAS G13-mutant CRCs and 1 HRAS melanoma....In this study, belva and cobi exhibited encouraging anti-tumor activity in NRASm and BRAFm (canonical and non-canonical) melanoma, and non-canonical BRAFm NSCLC.
Source:
Title:
A phase Ib trial of belvarafenib in combination with cobimetinib in patients with advanced solid tumors: Interim results of dose-escalation and patients with NRAS-mutant melanoma of dose-expansion.
Published date:
05/19/2021
Excerpt:
Belvarafenib in combination with cobimetinib showed acceptable tolerability and encouraging efficacy in NRASm melanoma, and in those with prior CPI treatment.
DOI:
10.1200/JCO.2021.39.15_suppl.3007
Trial ID:
Source:
Title:
Belvarafenib penetrates the BBB and shows potent antitumor activity in a murine melanoma brain metastasis model
Published date:
02/10/2023
Excerpt:
Belvarafenib strongly suppressed melanoma in BRAF V600E mutant A375SM tumor-bearing mice. It also significantly inhibited tumor growth in NRAS mutant SK-MEL-30 and K1735 tumor-bearing mice and synergized to enhance the antitumor activity combined with cobimetinib or atezolizumab.
DOI:
10.1007/s10585-023-10198-7
